B32B3 analogs

B32B3 analogs are a series of small molecule compounds developed as derivatives of the DCAF1 (VPRBP) kinase inhibitor B32B3. Although initially designed to target the kinase activity of DDB1-and-CUL4-associated factor 1 (DCAF1), subsequent characterization revealed that these analogs primarily function as microtubular destabilizing agents. This microtubule-disrupting activity is independent of DCAF1 kinase substrate dephosphorylation and leads to potent anti-tumor effects. These compounds have demonstrated significant activity against multiple myeloma and lymphoma in preclinical models, including in vivo efficacy, by perturbing cellular processes essential for the survival of plasma cell malignancies.